Catalyst-Rich 6 Months Ahead for Neurocrine Bio. (NBIX), Cowen Notes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff pulls Wall Street to two-week lows as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Tech selloff pulls Wall Street to two-week lows as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
Neurocrine Biosciences (NBIX) Tops Q2 EPS by 1c
July 29, 2015 5:30 PM EDTNeurocrine Biosciences (NASDAQ: NBIX) reported Q2 EPS of ($0.28), $0.01 better than the analyst estimate of ($0.29).
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
... More